Profound Medical Corp. shareholders elected two new directors at the company's June 14 annual meeting.
Arthur Rosenthal and Brian Ellacott will serve as independent directors of Ontario-based Profound Medical.
Rosenthal is CEO of gEyeCue Ltd., a development stage medical device company. His previous roles include senior vice president and chief scientific officer of Boston Scientific Corp. and vice president of research and development at C. R. Bard Inc., now a unit of Becton Dickinson and Co.
Ellacott is CEO of Belmont Instrument Corp., a medical device company focused on fluid warming and infusion systems. Previously, he was president and CEO of Laborie Medical Technologies.
Medical device company Profound Medical develops and sells technologies to ablate the prostate gland in patients with prostate cancer.